Last reviewed · How we verify
Doravirine + tenofovir DF + lamivudine
This combination inhibits HIV reverse transcriptase and integrase to block viral replication at multiple steps.
This combination inhibits HIV reverse transcriptase and integrase to block viral replication at multiple steps. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | Doravirine + tenofovir DF + lamivudine |
|---|---|
| Also known as | Delstrigo |
| Sponsor | Instituto Mexicano del Seguro Social |
| Drug class | Antiretroviral combination (NNRTI + NRTIs) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV reverse transcriptase. Tenofovir DF and lamivudine are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that are incorporated into the growing viral DNA chain, causing chain termination. Together, these three agents target reverse transcriptase through complementary mechanisms to suppress HIV replication.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Nausea
- Diarrhea
- Headache
- Rash
- Renal impairment (tenofovir-related)
- Bone density loss (tenofovir-related)
Key clinical trials
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) (PHASE2)
- Doravirine Dose Optimisation in Pregnancy (PHASE4)
- Efficacy and Safety of Doravirine in the Rapid Initiation (PHASE4)
- DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study (PHASE4)
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |